Bedford Works to Ease Leucovorin Shortage, Plans Another Lot Release

Bedford Laboratories is making progress in alleviating a shortage of the chemotherapy drug leucovorin calcium, prompted by manufacturing delays, and is working to expand its overall production capacity.

The company, which is the generic arm of Boehringer Ingelheim’s contract manufacturing subsidiary Ben Venue Laboratories, released one lot of 29,200 units of leucovorin calcium 350 mg Feb. 12 and plans to release three more lots this month, Bedford spokesman Jason Kurtz said.

Leucovorin calcium is an important part of a first-line treatment of metastatic colorectal cancer and adjuvant therapy for earlier stage disease, according to the National Cancer Institute’s NCI Cancer Bulletin. The drug is used in combination with fluorouracil.
Drug GMP Report